Impact of plasma concentration of transferrin on targeting capacity of nanoparticles.


Journal

Nanoscale
ISSN: 2040-3372
Titre abrégé: Nanoscale
Pays: England
ID NLM: 101525249

Informations de publication

Date de publication:
27 Feb 2020
Historique:
pubmed: 14 2 2020
medline: 15 12 2020
entrez: 14 2 2020
Statut: ppublish

Résumé

It is becoming increasingly accepted that various diseases have a capacity to alter the composition of plasma proteins. This alteration in protein composition may consequently change the targeting capacity of nanoparticles (NPs). In this study, the impact of a model targeting ligand's (i.e., Transferrin; Tf) concentration in human plasma on the targeting capacity of gold NPs (Au NPs), pre-conjugated with Tf, is investigated. Our findings demonstrate that the protein corona formation by both healthy and Tf depleted human plasma diminishes the targeting efficacy of Au NPs within human cancer cells despite a preservation of targeting ability by plasma with excess Tf (10-fold). Moreover, the plasma samples obtained from patients with various Tf levels (e.g., thalassemia major, sickle cell anemia, aplastic anemia, and iron deficiency anemia) have affected the accessibility of the targeting Tf in the corona layer and subsequently affected their targeting ability, which emphasizes the critical role of disease-specific protein corona on the efficacy of Au NPs. Ultimately, variations of protein concentration (e.g., due to disease occurrence and progress) in plasma affect its recruiting in corona formation, and in turn, affect the targeting and therapeutic efficacies of Au NPs.

Identifiants

pubmed: 32051994
doi: 10.1039/c9nr08784b
doi:

Substances chimiques

Protein Corona 0
Transferrin 0
Gold 7440-57-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4935-4944

Auteurs

Mohammad Reza Sepand (MR)

Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. mhghahremani@tums.ac.ir.

Mahdi Ghavami (M)

Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.

Steven Zanganeh (S)

Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10065, USA.

Sabrina Stacks (S)

Vassar College address 124 Raymond Ave, Poughkeepsie, NY 12604, USA.

Forough Ghasemi (F)

Department of Nanotechnology, Agricultural Biotechnology Research Institute of Iran (ABRII), Agricultural Research, Education, and Extension Organization (AREEO), Karaj, Iran.

Hamed Montazeri (H)

School of Pharmacy-International Campus, Iran University of Medical Sciences, Tehran, Iran.

Claudia Corbo (C)

School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy and Nanomedicine Center NANOMIB, University of Milano-Bicocca, Milano, Italy.

Hossein Derakhshankhah (H)

Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Seyed Nasser Ostad (SN)

Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. mhghahremani@tums.ac.ir.

Mohammad Hossein Ghahremani (MH)

Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. mhghahremani@tums.ac.ir.

Morteza Mahmoudi (M)

Department of Radiology and Precision Health Program, MI 48824, USA. mahmou22@msu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH